| Biomarker ID | 1192 |
| PMID | 23918943 |
| Year | 2013 |
| Biomarker | Methylation Status of HAPLN3 (High vs. Low) |
| Biomarker Basis | Methylation Based |
| Biomolecule | Methylation |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Hypermethylated in Prostate Cancer |
| Odds Ratio/Hazard Ratio/Relative Risk | Cohort 1: univariate : [HR = 1.83 (95% CI: 1.18-2.83) p-value=0.007, AUC= 0.58]; multivariate : [HR = 1.40 (95% CI: 0.85-2.29), p-value= 0.184]; Cohort 2: univariate : [HR = 1.727 (95% CI: 0.890-3.353), p-value= 0.106, AUC= 0.58] |
| Effect on Pathways | Pathways include: PASK human kinase ARCHS4 coexpression, PIM2 human kinase ARCHS4 coexpression, RIPK1 human kinase ARCHS4 coexpression, PRKX human kinase ARCHS4 coexpression, TESK2 human kinase ARCHS4 coexpression |
| Experiment | Biochemical recurrence |
| Type of Biomarker | Prognostic |
| Cohort | Nonmalignant samples [(adjacent normal [ADJ-N], benign prostatic hyperplasia (BPH)( n = 35)] and radical prostatectomy (RP) samples (n = 293) were chosen for the study |
| Senstivity | NA |
| Specificity | NA |
| AUC | 0.928 |
| Accuracy | NA |
| Level Of Significance | P < 0.001 |
| Method Used | quantitative methylation specific PCR |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | HAPLN3 |